Two new drugs for advanced HER2-positive breast cancer were shown progress in separate studies, and scientists say they've made progress in the development of new treatment options, CNN reports. 

One study found that adding the experimental drug tucatinib to a chemotherapy regimen consisting of the drugs trastuzumab and capecitabine could improve survival for adults with advanced HER2-positive metastatic breast cancer.

Read the whole study HERE

The other study found that the experimental drug conjugate called trastuzumab deruxtecan was able to substantially reduce tumor.

Read the whole study HERE

Both studies are evaluating new drugs for HER2-positive breast cancer, which represents about 15% to 20% of all breast cancers," said Dr. Eric Winer, chief of the division of breast oncology at Dana-Farber Cancer Institute in Boston and professor of medicine at Harvard Medical School, who was the senior author of the tucatinib study.